Karen L. Marquis

Pfizer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index3.3kcitations64works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(30), Neuroscience and Neuropharmacology Research(23), Neurotransmitter Receptor Influence on Behavior(21), Pharmacological Receptor Mechanisms and Effects(10), Ion channel regulation and function(7)

Publications64 total

Novel triazines as potent and selective phosphodiesterase 10A inhibitors
Bioorganic & Medicinal Chemistry Letters·2012· 26 citedOpen Access
5‐HT<sub>2C</sub>and 5‐HT<sub>6</sub>Receptor Targeted Emerging Approaches in Schizophrenia
2012· 1 cited
5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia
Handbook of experimental pharmacology·2012· 42 cited
Highly Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitors
Journal of Medicinal Chemistry·2011· 72 citedOpen Access
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625
Psychopharmacology·2011· 20 cited
P.3.d.005 Activity of phosphodiesterase 10A inhibitors in a novel animal model of negative symptoms of schizophrenia
European Neuropsychopharmacology·2010
Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonists Containing a Urea Moiety: Identification and Characterization of the Potent, Selective, and Orally Efficacious Agonist 1-[6-(4-Fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) Urea (SEN34625/WYE-103914)
Journal of Medicinal Chemistry·2010· 30 citedOpen Access
Discovery of Imidazo[1,5-<i>a</i>]pyrido[3,2-<i>e</i>]pyrazines as a New Class of Phosphodiesterase 10A Inhibitiors
Journal of Medicinal Chemistry·2010· 63 citedOpen Access
COMPOUND 1, A POTENT AND SELECTIVE DAO INHIBITOR, DEMONSTRATES EFFICACY IN SEVERAL PRECLINICAL ANIMAL MODELS OF SCHIZOPHRENIA
Schizophrenia Research·2010
Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia
Bioorganic & Medicinal Chemistry Letters·2010· 23 citedOpen Access
Temporal dysregulation of cortical gene expression in the isolation reared Wistar rat
Journal of Neurochemistry·2010· 20 cited
Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology·2009· 6 cited
Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology·2009· 59 cited
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity
Journal of Pharmacology and Experimental Therapeutics·2009· 14 cited
The orphan GPCR, GPR88, modulates function of the striatal dopamine system: A possible therapeutic target for psychiatric disorders?
Molecular and Cellular Neuroscience·2009· 94 cited
Characterization of the alpha-7 nicotinic receptor agonist WYE-103914 in models relevant to schizophrenia and interaction with antipsychotics
Biochemical Pharmacology·2009
In vitro pharmacological characterization and pro-cognitive effects of the selective alpha-7 nicotinic agonist WYE-103914
Biochemical Pharmacology·2009
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
Bioorganic & Medicinal Chemistry Letters·2009· 18 citedOpen Access
Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
Journal of Pharmacology and Experimental Therapeutics·2009· 266 cited
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
Neuropharmacology·2009· 145 cited
page 1 of 4Next →

Frequent Co-authors

Julie Brennan(16), Sharon Rosenzweig‐Lipson(13), Terrance H. Andree(12), Nicholas J. Brandon(10), Steven M. Grauer(10), Rachel L. Navarra(9), Radka Graf(9), Menelas N. Pangalos(8), Thomas A. Comery(7), Gary Stack(7), John Dunlop(7), Joseph Coupet(7), J. Edward Moreton(7), Richard E. Mewshaw(7), Xiaojie Shi(7), Steve Grauer(6), Sheree F. Logue(6), Mark H. Pausch(6), Zoë A. Hughes(6), Albert J. Robichaud(6)